Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
Clinical trial NCT05156281 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05156281
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-13
- Primary completion
- 2026-07-22
- Enrollment
- 1007
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.